The UK Government has launched a joint public-private investment programme worth up to £400 million to enhance its clinical trials infrastructure and boost the life sciences sector. This funding will create 18 new clinical trials hubs across the UK, enabling faster access to innovative treatments for NHS patients. Additionally, the investment will support sustainable pharmaceutical manufacturing and modernise Health Technology Assessment (HTA) processes, further strengthening the UK's position in global health research and innovation.

‍CEO & Founder of uMed Dr Matt Wilson provides his thoughts on the news:

‍“This investment is fantastic news, and a needed boost for research and innovation in the UK.  Great to see that this programme recognising the need to improve infrastructure, and supporting technology to make it easier for patients to participate and less burdensome for staff. The industry needs improved recruitment strategies to ensure participation from representative patient populations, targeted engagement, faster screening and better communication between patients, trial sites and sponsors.”